View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong

The Week Ahead in Life Sciences

Arcus Biosciences (RCUS) Feb. 28, 2026: Additional ARC-20 data including activity and biomarker analysis of cas in ccRCCAscendis Pharma (ASND) Feb. 28, 2026: PDUFA date for TransCon CNP for pediatric achondroplasiaBioMarin Pharmaceutical (BMRN) Feb. 28, 2026: PDUFA date for Palynziq for adolescent

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 21, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 20, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarte...

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and business updates. To join a webcast of the call, please visit this . To join the teleconfe...

 PRESS RELEASE

Shenandoah Telecommunications to Participate in March 2026 Investor Co...

Shenandoah Telecommunications to Participate in March 2026 Investor Conferences EDINBURG, Va., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (Shentel) (NASDAQ:SHEN) announced that Ed McKay, Chief Executive Officer, and Jim Volk, Chief Financial Officer will be participating in the following investor conferences in March 2026: The 2026 Morgan Stanley Technology, Media & Telecom Conference being held at the Palace Hotel, San Francisco, CA. Jim Volk will present on March 3, 2026 at 4:05PM PT. Investors may access a live webcast of the presentation at this or at ou...

 PRESS RELEASE

Shentel’s Employee Volunteer Initiative Gives Back to Local Charities

Shentel’s Employee Volunteer Initiative Gives Back to Local Charities EDINBURG, Va., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (Shentel) (Nasdaq: SHEN), a leading broadband service provider, announced today that 114 employees contributed more than 572 volunteer hours over the past year in support of charitable organizations focused on addressing food and housing insecurity in the communities the Company serves. These efforts reflect Shentel’s deep-rooted commitment to community service and its belief that meaningful impact starts with employees who are connec...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 14, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 13, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 12, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing R...

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 30,600 shares of Intellia’s common...

 PRESS RELEASE

Shenandoah Telecommunications Company to Hold its Fourth Quarter and F...

Shenandoah Telecommunications Company to Hold its Fourth Quarter and Full Year 2025 Earnings Call at 8:30 a.m. on Thursday, February 26, 2026 EDINBURG, Va., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (Shentel) (NASDAQ:SHEN) will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026, and will host a conference call and simultaneous webcast on the same day at 8:30 a.m. Eastern Time to discuss Shentel’s financial results and business highlights. Date: February 26, 2026Time: 8:30 AM ET Listen via I...

 PRESS RELEASE

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE...

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug ap...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 13, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Glo Fiber Launches 8 Gig Fiber Internet Service

Glo Fiber Launches 8 Gig Fiber Internet Service EDINBURG, Va., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Glo Fiber, powered by Shenandoah Telecommunications Company (Shentel) (Nasdaq: SHEN), has launched symmetrical 8 Gig fiber internet service for residential customers across Virginia, West Virginia, Maryland, Pennsylvania, Delaware, and Ohio. More than 400,000 homes and businesses now have access to Glo Fiber’s 100% fiber optic network and the fastest broadband speeds available in these markets. “Integrating 8 Gig internet service into our multi-gig product portfolio ensures Glo Fiber continue...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 9, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Triplepoint Venture Growth Bdc Corp: 1 director

A director at Triplepoint Venture Growth Bdc Corp bought 47,710 shares at 6.493USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch